Emcure Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 28, 2025
EMCURE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Emcure Pharmaceuticals held its 44th AGM on August 28, 2025, via video conferencing, chaired by Mr. Berjis Desai. The meeting lasted from 11:00 AM to 12:25 PM and had the requisite quorum. Members approved 12 resolutions, including the adoption of audited standalone and consolidated financial statements for FY25, declaration of a final dividend of Rs. 3 per equity share (face value Rs. 10), and re-appointment of Mr. Sunil Mehta and Mr. Samit Mehta as directors retiring by rotation. The meeting also approved the re-appointment of Dr. Mukund Gurjar as Whole-time Director, appointment of SVD & Associates as Secretarial Auditors, and remuneration for executive directors including MD & CEO Satish Mehta. Statutory Auditor's and Secretarial Audit Reports had no qualifications. MD Satish Mehta briefed members on operations, sustainability initiatives, outlook, strategic priorities, and digital transformation.
Positive for shareholders due to the declared dividend of Rs. 3 per share; routine corporate housekeeping with all key resolutions expected to pass, indicating stable governance. The clean audit reports and strategic focus on sustainability and digital transformation suggest business continuity without red flags.